Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
729 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05129280 | A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors | terminated | Phase 1 | 23 | Hoffmann-La RocheINDUSTRY | 6 | Aug 4, 2023 | clinicaltrials |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy | terminated | Phase 1 / Phase 2 | 8 | GenmabINDUSTRY | 3 | Aug 3, 2023 |
| NCT01054625 | Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | completed | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 4 | Aug 3, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT00677924 | Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer(GEN206) | terminated | Phase 1 / Phase 2 | 9 | GenmabINDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT03637764 | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 107 | SanofiINDUSTRY | 8 | Jul 10, 2023 | clinicaltrials |
| NCT03724071 | Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. | terminated | Phase 1 / Phase 2 | 51 | TransgeneINDUSTRY | 3 | Jun 23, 2023 | clinicaltrials |
| NCT04616729 | DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation(Depo-Trigger) | unknown | Phase 1 / Phase 2 | 30 | Universitair Ziekenhuis BrusselOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT01794520 | Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 117 | AbbVieINDUSTRY | 4 | Apr 10, 2023 | clinicaltrials |
| NCT01582776 | Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma | completed | Phase 1 / Phase 2 | 317 | The Lymphoma Academic Research OrganisationOTHER | 2 | Mar 17, 2023 | clinicaltrials |
| NCT05187858 | A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 | 15 | Lupin Ltd.INDUSTRY | 3 | Mar 17, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03916744 | A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer | completed | Phase 1 | 75 | Genentech, Inc.INDUSTRY | 5 | Mar 10, 2023 | clinicaltrials |
| NCT02598960 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. | completed | Phase 1 / Phase 2 | 295 | Bristol-Myers SquibbINDUSTRY | 10 | Mar 6, 2023 | clinicaltrials |
| NCT04202705 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 | completed | Phase 1 | 31 | Byondis B.V.INDUSTRY | 2 | Jan 30, 2023 | clinicaltrials |
| NCT02713529 | Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 117 | AmMax Bio, Inc.INDUSTRY | 6 | Jan 20, 2023 | clinicaltrials |
| NCT02748200 | External Beam Radiotherapy for Muscle Invasive Bladder Cancer | completed | Phase 1 | 77 | University Hospital, GhentOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT00528294 | Phase I Trial From GRID 18F-FDG-PET Biological Imaging-guided Intensitymodulated Radiotherapy (BG-IMRT) With Patients With Recurrent or New Head or Neck Tumor in Previously Radiated Area | terminated | Phase 1 | 12 | University Hospital, GhentOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT04042116 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | suspended | Phase 1 / Phase 2 | 227 | Clovis Oncology, Inc.INDUSTRY | 6 | Dec 20, 2022 | clinicaltrials |
| NCT01116804 | Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 36 | University Hospital, GhentOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT00135161 | Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer | completed | Phase 1 | 40 | University Hospital, GhentOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT02627274 | A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 9 | Nov 22, 2022 | clinicaltrials |
| NCT00807859 | Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | completed | Phase 1 | 65 | AmgenINDUSTRY | 3 | Nov 8, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT00145158 | Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma | terminated | Phase 1 / Phase 2 | 23 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT00145145 | Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT04551352 | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | completed | Phase 1 | 20 | Hoffmann-La RocheINDUSTRY | 6 | Oct 3, 2022 | clinicaltrials |
| NCT02341625 | A Study of BMS-986148 in Patients With Select Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 126 | Bristol-Myers SquibbINDUSTRY | 7 | Aug 18, 2022 | clinicaltrials |
| NCT02650817 | Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer | completed | Phase 1 | 16 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT05506332 | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03064854 | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | terminated | Phase 1 | 111 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 15, 2022 | clinicaltrials |
| NCT04258592 | 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors | terminated | Phase 1 | 6 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT02734615 | Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers | terminated | Phase 1 | 199 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 1, 2022 | clinicaltrials |
| NCT03517956 | Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors(ROCOCO) | completed | Phase 1 | 16 | BayerINDUSTRY | 6 | Jul 14, 2022 | clinicaltrials |
| NCT03102320 | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors(ARCS-Multi) | completed | Phase 1 | 173 | BayerINDUSTRY | 12 | Jun 30, 2022 | clinicaltrials |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | completed | Phase 1 | 250 | Blueprint Medicines CorporationINDUSTRY | 10 | Jun 21, 2022 | clinicaltrials |
| NCT04632316 | A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 33 | Glycostem Therapeutics BVINDUSTRY | 5 | Jun 21, 2022 | clinicaltrials |
| NCT01429038 | Mesenchymal Stem Cells After Renal or Liver Transplantation | completed | Phase 1 / Phase 2 | 40 | University of LiegeOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03788083 | Intratumoral TriMix Injections in Early Breast Cancer Patients(TMBA) | unknown | Phase 1 | 36 | Universitair Ziekenhuis BrusselOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT01587040 | Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen | completed | Phase 1 / Phase 2 | 61 | SanofiINDUSTRY | 4 | Apr 19, 2022 | clinicaltrials |
| NCT03000257 | A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | AbbVieINDUSTRY | 10 | Apr 14, 2022 | clinicaltrials |
| NCT02384850 | Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer(SENTINEL) | terminated | Phase 1 | 10 | GSO Global Clinical Research BVOTHER | 2 | Apr 8, 2022 | clinicaltrials |
| NCT02978755 | First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers | completed | Phase 1 | 78 | GamaMabs PharmaINDUSTRY | 3 | Apr 6, 2022 | clinicaltrials |
| NCT02410512 | A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 610 | Genentech, Inc.INDUSTRY | 7 | Apr 1, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials